Elanco Reports $1.137 Billion Revenue in Q3 2025, Faces $34 Million Net Loss

Elanco Animal Health Incorporated reported a revenue of $1.137 billion for the third quarter of 2025, marking a 10% increase from $1.030 billion in the same period of 2024. For the nine months ending September 30, 2025, the company generated $3.571 billion in revenue, up 4% from $3.419 billion year-over-year. Despite the revenue growth, Elanco recorded a net loss of $34 million for the third quarter, a significant decline from a net income of $364 million in the prior year, primarily due to a lack of gains from divestitures that had positively impacted the previous year's results.

The company's cost of sales increased to $530 million in Q3 2025 from $492 million in Q3 2024, contributing to a gross profit of $607 million, which was a 13% increase compared to $538 million in the prior year. The gross margin improved slightly to 53% from 52%. Research and development expenses rose marginally to $89 million, while marketing, selling, and administrative expenses increased to $351 million, reflecting strategic investments in product launches and sales efforts.

Elanco's operational metrics showed a positive trend, with notable increases in customer engagement and product adoption. The company reported strong performance in its pet health segment, with revenue rising to $533 million, driven by new product launches such as Credelio Quattro and Zenrelia. The farm animal segment also saw growth, with revenue reaching $593 million, bolstered by increased sales in cattle and poultry. However, the company faced challenges from accelerated customer purchases in anticipation of tariff increases, which may have shifted some revenue from Q3 to Q2.

Strategically, Elanco has been active in acquisitions and divestitures, including the sale of its aqua business in July 2024 for $1.294 billion, which significantly impacted its financials last year. The company also acquired a manufacturing facility in Speke, U.K., for $36 million to enhance its production capabilities. Looking ahead, Elanco anticipates continued growth driven by its product pipeline and market expansion, although it remains cautious about macroeconomic conditions and regulatory changes that could affect its operations. The company is focused on maintaining liquidity, with $505 million in cash and cash equivalents as of September 30, 2025, and plans to leverage its credit facilities for future investments.